– USA, NJ – Bristol Myers Squibb (NYSE: BMY) today announced the election of Michael R. McMullen to its Board as an independent director, effective July 1, 2024, bringing the Board to 11 members.
“We are pleased to welcome Mr. Michael McMullen to our Board of Directors. Mike’s extensive experience in managing large businesses and global operations, combined with his proven track record of delivering excellent shareholder returns, will prove valuable as we continue to strengthen the company’s long-term growth profile, progress our pipeline, and prioritize opportunities where we see the highest return for our patients and shareholders,” said Chair and CEO, Dr. Christopher Boerner.
Mr. McMullen will also join the Audit Committee.
About Michael R. McMullen
Mr. McMullen previously served as president and CEO of Agilent Technologies, Inc. from 2015-2024. He brings to the Board more than 20 years of executive experience and leadership skills. During his tenure as CEO, he led Agilent’s transformation into a market-leading life sciences and diagnostics company, nearly tripled its market capitalization, and drove a business and cultural transformation that led to significant improvements in growth and improved profitability. He is currently serving as a senior advisor to Agilent and its new CEO until October 31, 2024.
Before becoming CEO of Agilent, Mr. McMullen served as COO from 2014-2015, as president of Agilent’s Chemical Analysis Group from 2009-2014 and held roles of increasing responsibilities from 1992-2009, including as VP and general manager of the Chemical Analysis Solutions Unit of the Life Sciences and Chemical Analysis Group and country manager for Agilent’s China, Japan and Korea Life Sciences and Chemical Analysis Group.
Mr. McMullen began his career when he joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a financial analyst.
Mr. McMullen received his M.B.A. with honors from the University of Pennsylvania’s Wharton School of Business. He received his undergraduate degree, with a double major in finance and economics, magna cum laude from the University of Delaware.
Mr. McMullen also serves on the board of directors of KLA Corporation and is a former director of Agilent and Coherent, Inc.
Mr. McMullen said: “I am pleased to be joining the Board of Bristol Myers Squibb, a company known and respected for its long history of innovation and scientific discovery. It’s an exciting time at Bristol Myers Squibb and I look forward to joining my fellow directors and the management team in helping the company realize the promise of the compelling opportunities ahead.”
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.